Spots Global Cancer Trial Database for Study of the Efficacy and Safety of Ublituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Study of the Efficacy and Safety of Ublituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
Official Title: An Open Label Phase I/II Study of the Efficacy and Safety of Ublituximab in Patients With B-cell Non-Hodgkin Lymphoma Who Have Relapsed or Are Refractory After CD20 Directed Antibody Therapy
Study ID: NCT01647971
Interventions
Study Description
Brief Summary: The purpose of this study is to determine whether ublituximab is safe and effective in patients with relapsed or refractory B-cell lymphoma who were previously treated with rituximab.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
TG Therapeutics Investigational Trial Site, Huntsville, Alabama, United States
TG Therapeutics Investigational Trial Site, Jonesboro, Arkansas, United States
TG Therapeutics Investigational Trial Site, Athens, Georgia, United States
TG Therapeutics Investigational Trial Site, Macon, Georgia, United States
TG Therapeutics Investigational Trial Site, Bethesda, Maryland, United States
TG Therapeutics Investigational Trial Site, Morristown, New Jersey, United States
TG Therapeutics Investigational Trial Site, New York, New York, United States
TG Therapeutics Investigational Trial Site, Memphis, Tennessee, United States
Contact Details
Name: TG Therapeutics Clinical Trials
Affiliation: TG Therapeutics, Inc.
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
